Clinical Trials
The James Cancer Center Columbus, OHopen for enrollment
Palbociclib + Anti-HER2 + Endo vs. Anti-HER2 + Endo Tafter Induct Tx for HR+/HER2-Pos Met Breast Can
Protocol: OSU-17311
Full Title
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
For More Information
See Full Trial at ClinicalTrials.gov